Sepantronium bromide is under clinical development by Beijing zhikangbo Medical Oncology Research and currently in Phase II for Burkitt Lymphoma. According to GlobalData, Phase II drugs for Burkitt Lymphoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sepantronium bromide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sepantronium bromide overview
Sepantronium bromide is under development for the treatment of relapsed or refractory high-grade B-cell lymphoma, neuroblastoma, Ewing sarcoma, Burkitt lymphoma and castration-resistant neuroendocrine prostate cancer (NEPC). The drug candidate is administered through intravenous injection. The drug candidate targets survivin protein.
Beijing zhikangbo Medical Oncology Research overview
Beijing zhikangbo Medical Oncology Research (Cothera Bioscience) focuses on the research and development of innovative tumor-targeted drugs. Cothera Bioscience is headquartered in Beijing, China.
For a complete picture of Sepantronium bromide’s drug-specific PTSR and LoA scores, buy the report here.